Fang Zhou

Prof. Fang Zhou

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
YSYunlong Shan
Yunlong Shan
MZMengying Zhang
Mengying Zhang
ETEnxiang Tao
Enxiang Tao
JWJing Wang
Jing Wang
NWNing Wei
Ning Wei
GWGuangji Wang
Guangji Wang
Over the past two decades, mesenchymal stem/stromal cell (MSC) therapy has made substantial strides, transitioning from experimental clinical applications to commercial products. MSC therapies hold considerable promise for treating refractory and critical conditions such as acute graft-versus-host disease, amyotrophic lateral sclerosis, and acute respiratory distress syndrome. Despite recent successes in clinical and commercial applications, MSC therapy still faces challenges when used as a commercial product. Current detection methods have limitations, leaving the dynamic biodistribution, persistence in injured tissues, and ultimate fate of MSCs in patients unclear. Clarifying the relationship between the pharmacokinetic characteristics of MSCs and their therapeutic effects is crucial for patient stratification and the formulation of precise therapeutic regimens. Moreover, the development of advanced imaging and tracking technologies is essential to address these clinical challenges. This review provides a comprehensive analysis of the kinetic properties, key regulatory molecules, different fates, and detection methods relevant to MSCs and discusses concerns in evaluating MSC druggability from the perspective of integrating pharmacokinetics and efficacy. A better understanding of these challenges could improve MSC clinical efficacy and speed up the introduction of MSC therapy products to the market.

1 December 2019 in Pharmacological Research
Verified
Journal Article
Closed access
SFSiqi Feng
Siqi Feng
HWHuan Wang
Huan Wang
JLJiali Liu
Jiali Liu
JAJiye Aa
Jiye Aa
FZFang Zhou
Fang Zhou
GWGuangji Wang
Guangji Wang

7 October 2022 in Pharmacological Research
Verified
Journal Article
Open access
QWQizhi Wang
Qizhi Wang
MWMing Wu
Ming Wu
HLHaobin Li
Haobin Li
XRXin Rao
Xin Rao
LALuyao Ao
Luyao Ao
FZFang Zhou
Fang Zhou
Acquired drug resistance and epithelial-mesenchymal transition (EMT) mediated metastasis are two highly interacting determinants for non-small-cell lung cancer (NSCLC) prognosis. This study investigated the common mechanisms of drug resistance and EMT from the perspective of metabolic reprogramming, which may offer new ideas to improve anticancer therapy. Acquired resistant cells were found to grow faster and have a greater migratory and invasive capacity than their parent cells. Metabolomics analysis revealed that acquired resistant cells highly relied on glutamine utilization and mainly fluxed into oxidative phosphorylation energy production. Further mechanistic studies screened out glutamate dehydrogenase 1 (GLUD1) as the determinant of glutamine addiction in acquired resistant NSCLC cells, and provided evidence that GLUD1-mediated α-KG production and the accompanying reactive oxygen species (ROS) accumulation primarily triggered migration and invasion by inducing Snail. Pharmacological and genetic interference with GLUD1 in vitro significantly reversed drug resistance and decreased cell migration and invasion capability. Lastly, the successful application of R162, a selective GLUD1 inhibitor, to overcome both acquired resistance and EMT-induced metastasis in vivo, identified GLUD1 as a promising and druggable therapeutic target for malignant progression of NSCLC. Collectively, our study offers a potential strategy for NSCLC therapy, especially for drug-resistant patients with highly expressed GLUD1.

4 June 2024 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
BCBin Chen
Bin Chen
CCCheng Cheng
Cheng Cheng
YWYunhao Wu
Yunhao Wu
SLSiyu Li
Siyu Li
MHMo Han
Mo Han
FZFang Zhou
Fang Zhou
Ototoxicity and nephrotoxicity are the most prevalent side effects of aminoglycoside antibiotics (gentamicin, amikacin, neomycin) and platinum anti-tumor drugs (cisplatin, carboplatin). The inner ear and kidney share similarities in drug deposition and toxicity, but the underlying pathophysiological mechanisms remain unclear. Investigating the shared mechanisms and metabolic alterations in these distinct organs will provide valuable insights for clinical therapy. A strong correlation has been identified between the spatiotemporal accumulation patterns of neomycin and the specific occurrence of lipid metabolism disorders in these two organs. The primary allocation of neomycin to mitochondria results in a notable escalation in the accumulation of lipid droplets (LDs) and more interactions between mitochondria and LDs, leading to a sequence of disturbances in lipid metabolism, such as increased lipid ROS and the blocked transfer of fatty acids from LDs to mitochondria. PGC-1α deficiency worsens the neomycin-induced disorders in lipid metabolism and intensifies the pathological interactions between mitochondria and LDs, as indicated by the exacerbated disturbance of dynamic LD turnover, increased level of oxidized lipids and decreased use of fatty acids. This investigation provides a fresh perspective on the lipid metabolic dysfunction related to mitochondria–LD interactions in drug-induced ototoxicity and nephrotoxicity, potentially providing novel avenues for intervention strategies.

22 February 2022 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
YSYunlong Shan
Yunlong Shan
QNQi Ni
Qi Ni
QZQixiang Zhang
Qixiang Zhang
MZMengying Zhang
Mengying Zhang
BWBin Wei
Bin Wei
FZFang Zhou
Fang Zhou
Vascular abnormality is a hallmark of most solid tumors and facilitates immune evasion. Targeting the abnormal metabolism of tumor endothelial cells (TECs) may provide an opportunity to improve the outcome of immunotherapy. Here, in comparison to vascular endothelial cells from adjacent peritumoral tissues in patients with colorectal cancer (CRC), TECs presented enhanced glycolysis with higher glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. Then an unbiased screening identified that osimertinib could modify the GAPDH and thus inhibit its activity in TECs. Low-dose osimertinib treatment caused tumor regression with vascular normalization and increased infiltration of immune effector cells in tumor, which was due to the reduced secretion of lactate from TECs by osimertinib through the inhibition of GAPDH. Moreover, osimertinib and anti-PD-1 blockade synergistically retarded tumor growth. This study provides a potential strategy to enhance immunotherapy by targeting the abnormal metabolism of TECs.

1 April 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
LCLingge Cheng
Lingge Cheng
WLWenyue Liu
Wenyue Liu
CZChongjin Zhong
Chongjin Zhong
PNPing Ni
Ping Ni
SNSuiying Ni
Suiying Ni
FZFang Zhou
Fang Zhou